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Proinﬂammatory and Prothrombotic Effects
of Hypoglycemia
H
ypoglycemia is known to be intrin-
sic to the treatment of diabetes be-
cause insulin is a powerful glucose-
lowering agent and sulfonylureas exert
their effect through insulin release by the
pancreatic -cells. Hypoglycemia occurs
in association with these two common
modes of therapy and was previously ac-
cepted as a part of the treatment of this
condition. With the arrival of other
modes of diabetes treatment, such as
metformin, thiazolidenediones, 2-
glucosidase inhibitors, and incretins,
which do not induce hypoglycemia ex-
cept when administered in combination
with insulin and sulfonylureas, the issue
of hypoglycemia has to be assessed in
the context of both the immediate risk
related to neuroglycopenia and the pos-
sible long-term risk of diabetic vascular
complications.
Vascular complications of hypoglyce-
mia have to be tackled with greater ur-
gency now because two recent trials of
intensiﬁed diabetes treatment with insu-
lin, the Action to Control Cardiovascular
RiskinDiabetes(ACCORD)trialandVet-
eran’s Affairs Diabetes Trial (VADT), did
notdemonstrateareductionincardiovas-
cular events (1,2). In fact, the intensiﬁed
insulin treatment arm of the ACCORD
trial had to be halted because of an in-
crease in overall mortality, despite a re-
duction in acute myocardial infarction.
The rate of hypoglycemia in both trials
was signiﬁcantly increased with intensi-
ﬁed insulin treatment. Although the anal-
ysis of the ACCORD data did not support
the hypothesis that the increased mortal-
ity in the study was a result of hypoglyce-
mia,thefactthathypoglycemiamayoften
be asymptomatic leaves us with the pos-
sibility that it may be responsible.
The fact that hypoglycemia results in
platelet hyperaggregability (3) and an in-
crease in several factors involved in the
coagulation cascade has been known for
over 2 decades. Activated partial throm-
boplastin time is shortened, ﬁbrinogen
and factor VIII increase, and platelet
counts fall in association with hypoglyce-
mia (4). More recently, two studies have
shown that hypoglycemia induces proin-
ﬂammatory changes including an in-
crease in the plasma concentration of
interleukin (IL)-6 (5) and increases in
other proinﬂammatory mediators, in-
cludingleucocytosis,reactiveoxygenspe-
cies(ROS)generation,lipidperoxidation,
and levels of tumor necrosis factor-
(TNF), IL-1, and IL-8 (5). Two studies
published in this issue of Diabetes Care
conﬁrm that hypoglycemia does, indeed,
induce an increase in proinﬂammatory
mediators and platelet activation, and has
an inhibitory effect on ﬁbrinolytic mech-
anisms. Wright et al. (6) and Gogitidze
Joyetal.(7)bothusedaninsulininfusion
to gradually induce hypoglycemia and
then clamped glucose at hypoglycemic
levels of 2.5 and 2.9 mmol/l, respectively.
The former maintained hypoglycemia for
60 min while the latter maintained it for
120 min. As is evident from the data, the
effects of the longer duration of hypogly-
cemia in the study by Gogitidze Joy et al.
are more impressive as reﬂected in the in-
crease in proinﬂammatory mediators, in
spite of the fact that glucose concentra-
tionswerenotaslowasthoseinthestudy
by Wright et al. The increases in the in-
dexes of inﬂammation and oxidative
stress in the study by Razavi Nematollahi
et al. (5) were even more impressive,
probably because the mode of induction
of hypoglycemia was by a bolus intrave-
nousinjection,whichledtoarapidfallin
blood glucose concentrations leading to a
rapid release of catecholamines and the
stimulationoftheinﬂammatoryresponse.
In the study by Wright et al., hypoglyce-
mia induced an increase in CD40 expres-
sion on mononuclear cells and plasma
concentration of CD40L, as well as an in-
crease in platelet-monocyte aggregates
and P-selectin concentrations with a
trend toward an increase in von Wille-
brand factor concentrations. In the study
by Gogitidze Joy et al., hypoglycemia led
to an increase in intercellular adhesion
molecule (ICAM), vascular cell adhesion
molecule (VCAM), P-selectin, and E-
selectin, as well as plasminogen activator
inhibitor-1 (PAI-1), TNF, IL-6, and vas-
cular endothelial growth factor (VEGF).
Bothofthesestudiesincludedcontrol
arms in which the effect of insulin infu-
sions administered at the same rates as
above were investigated while maintain-
ing glucose concentrations in the normal
range through the appropriate titration of
glucose infusion rates. Both studies con-
ﬁrmed the presence of an anti-inﬂamma-
tory effect of insulin during infusions
when euglycemia was maintained (8).
Again,theanti-inﬂammatoryeffectsofin-
sulin were more impressive in the study
by Gogitidze Joy et al. because they main-
tainedtheinfusionofinsulinfor120min,
whereasthestudybyWrightetal.infused
insulin for only 60 min. Previous work
has consistently shown impressive anti-
inﬂammatoryeffectsofinsulininfusedfor
120 min or more (8). Thus, in situations
where insulin infusions are used for the
anti-inﬂammatory and cardioprotective
actions of insulin, extreme care has to be
exercised because hypoglycemia reverses
the effects of euglycemic hyperinsulin-
emia. It is of interest that hypoglycemia
exerts proinﬂammatory effects similar to
those of hyperglycemia and glucose in-
take (9,10).
Clearly, hypoglycemia results in the
induction of rapid inﬂammatory, plate-
let proaggregatory, antiﬁbrinolytic, and
prothrombotic responses. This effect of hy-
poglycemia overrides the anti-inﬂamma-
tory, antiplatelet, and proﬁbrinolytic
effects of insulin observed under euglyce-
mic conditions. In addition, there is also
an increase in ROS generation and lipid
peroxidation, reﬂecting oxidative stress.
Although the hypoglycemic episodes are
transient, repeated occurrences of such
episodesmayhavecumulativeeffectsthat
are detrimental to inﬂammation-based
processes such as atherogenesis and its
thrombotic complications. These detri-
mental effects would add to the previ-
ously demonstrated relationship between
both silent and symptomatic hypoglyce-
mia on cardiac angina. In one study in-
volving diabetic patients with coronary
heart disease who were continuously
monitored for blood glucose concentra-
tionsandelectrocardiographicchanges,it
was demonstrated that there was chest
pain associated with hypoglycemia in
20% of the patients, of whom 40% had
concomitant electrocardiogram (ECG)
changes consistent with ischemia (11).
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sociated with ECG changes of ischemia in
14%. In this study, it was also observed
that a rapid fall in glucose of 100 mg/dl
per hour was more likely to be associated
with chest pain and ECG changes of isch-
emia. This likely vasoconstrictor effect of
hypoglycemia on coronary circulation is
also probably attributable to cat-
echolamines. This article does not com-
ment on the occurrence of dysrythmia;
however, the sudden release of cat-
echolamines is also conducive to the in-
duction of abnormal cardiac rhythms.
Collectively, therefore, hypoglycemia can
trigger a sequence of events that may be
extremely detrimental from the cardiac
point of view.
It is important to note that the rapid-
ity of the onset of hypoglycemia is also a
major determinant of the proinﬂamma-
tory changes. Further studies are neces-
sary to increase our understanding of the
pathophysiology of hypoglycemia and its
relationship with inﬂammation, platelet
aggregation, and thrombotic mecha-
nisms. In addition, we also need further
information on the effects of the severity,
duration, and rapidity of hypoglycemia
development. Such studies are even more
important and urgent because insulin is
now being used in the intensive care set-
tinginveryillpatientswithprofoundand
severe inﬂammation in association with
theactivationofthromboticmechanisms.
To add to these challenges, there are also
the contrasting effects of spontaneous hy-
poglycemia, which carries a bad progno-
sis, whereas that induced by insulin does
not, in patients with acute myocardial in-
farction (12,13).
Another important aspect of the
pathophysiologyofhypoglycemiaisitsef-
fect on the brain. In addition to the obvi-
ous short- and long-term effects of
neuroglycopenia, the brain is also vulner-
able to systemic inﬂammation because
cytokines from the circulation can poten-
tially enter the brain, activate the micro-
glia (the representatives of macrophages
in the central nervous system), and acti-
vate a damaging, neurotoxic sequence of
events (14). Whether hypoglycemia-
induced catecholamine release also exerts
a proinﬂammatory effect on microglia re-
quires further investigation (15). It
should be noted that repeated hypoglyce-
mia and hypoglycemia-related deaths are
associated with signiﬁcant changes in the
hippocampus and the dentate gyrus
(16,17).
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